Neoadjuvant EGFR TKI trials in NSCLC

Julia Rotow, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the use of neoadjuvant EGFR TKI, an emerging strategy in the management of non-small cell lung cancer (NSCLC), highlighting the importance of moving novel approaches into earlier treatment lines to improve patient outcomes. Dr Rotow also touches on the NeoADAURA trial (NCT04351555) which will evaluate neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone prior to surgery, in patients with resectable stage II-IIIB N2 EGFR mutation-positive NSCLC. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.